Kairos Pharma, Ltd. (NYSE American: KAPA) presented preclinical data on its investigational compound KROS 101 at the 13th AACR-JCA Joint Conference, held from February 1-5, 2025. The presentation, titled 'KROS 101: A Next-Generation GITR Agonist Boosting Anti-Tumor T Cell Responses and Reprogramming the Tumor Microenvironment,' highlighted recent in vivo findings.
The results demonstrated that KROS 101 is a potent GITR ligand agonist capable of enhancing T cell infiltration, proliferation, and the ability to kill cancer cells in mouse models of melanoma and in human glioblastoma in vitro. Furthermore, KROS 101 effectively reduced T reg-mediated suppression, which is crucial for augmenting antitumor immune responses.
In a preclinical study, KROS 101 reduced melanoma tumor in a human GITR knock-in mouse model, showing significant activity compared to mice treated with the GITR antibody TRX518. This data supports the potential of KROS 101 to exploit GITR as a lever for T cell expansion and a novel therapy for cancer.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.